ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment